Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Asan Medical Center
With
Eli Lilly and Company
We designed a multi-center phase II trial of gemcitabine for advanced stage marginal zone B-cell lymphoma. Marginal zone lymphoma needs novel agent to improve clinical course by chemotherapy. Recent trials with new agents for indolent lymphoma shows promising results. Gemcitabine is known to have activity to non-Hodgkin's lymphoma and has less adverse effects than other new agents. With this background gemcitabine will be tried as a single agent for advanced marginal zone lymphoma.
Gemcitabine will be administered with 1,250mg/sq.m on days 1 and 8 every 3 weeks. Response will be assessed by IWC criteria.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed marginal zone B-cell lymphoma
Performance status (ECOG) ≤3
Age ≥ 18
At least one or more bidimensionally measurable lesion(s):
* 2 cm by conventional CT
* 1 cm by spiral CT
* skin lesion (photographs should be taken)
* measurable lesion by physical examination
Laboratory values:
* Cr \< 2.0 mg% or Ccr \> 60 ml/min
* Transaminase \< 3 X upper normal value
* Bilirubin \< 2 mg%
* ANC \> 1500/ul, platelet \> 75,000/ul
Informed consent
Ann Arbor stage III or IV
You may not be if
Any other malignancies within the past 5 years except skin basal cell ca or CIS of cervix
Serious comorbid diseases
Pregnancy or breast feeding
Clareo Health | Gemcitabine for Marginal Zone Lymphoma
